A talk by the CEO of BiosparQ, on their mass spec solution for medical microbiology.

1. BiosparQ, a paradigm shift
in medical microbiology
Gerold de Valk, Dec 13th 2012
1

2. Introducing BiosparQ BV
• TNO spin-off company, 2009 (Leiden Bio Science Park)
• 3 staff (applied physics, high tech equipment)
• 6 M€ series A funding, 2012 (Dutch informal investor)
6-3-2013 2

3. Our vision
• A paradigm shift in medical microbiology
Better and safer patient care
Much lower cost
6-3-2013 Company Confidential 3

4. Microbiology in 2009
6-3-2013 Company Confidential 4

5. Microbiology in 2012
6-3-2013 Company Confidential 5

6. Microbiology paradigm shift
6-3-2013 Company Confidential 6

7. Requirements
• Faster (minutes instead of hours/days)
• Better (polymicrobial infections, quantitative data)
• Fieldable (no laboratory infrastructure needed)
• Affordable
• Easy to use
 Radical innovation, shaping a new future for medical
microbiology
6-3-2013 Company Confidential 7

8. How?
Single cell MALDI TOF mass spectrometry
6-3-2013 Company Confidential 8

9. Development status
6-3-2013 Company Confidential 9

10. Thank you
9-5-2012 10